Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the independent Data Monitoring Committee recommended suspension of enrollment.

11 Apr 2011

Democratic Congresswoman highlights threat climate change poses to public health

Rep. Lois Capps (D-Calif.) "called climate change a bigger public health threat than AIDS, malaria and pandemic flu" before a vote on Wednesday on a bill aimed at thwarting Environmental Protection Agency climate regulations, The Hill's "E2-Wire" blog reports.

8 Apr 2011

Top 10 global pharmaceutical company, Medicago sign deal to develop non-influenza vaccine

Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company.

7 Apr 2011

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

Aragen Bioscience, Inc., today announced it is a subcontractor on a National Institute of Allergy and Infectious Diseases contract for the preclinical development of monoclonal antibodies for the prevention and treatment of infectious diseases.

6 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

Novavax, Inc. announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today. In its tenth annual list of promising clinical compounds, R&D Directions cited Novavax's virus-like-particle technology as a promising new approach to producing vaccines to prevent seasonal, H1N1 and avian influenza. The list reflects the current interests of industry observers and analysts and is described in the magazine's March 2011 issue.

5 Apr 2011

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

A contract has been awarded to develop a long-acting single-dose antiviral drug for use in the United States, the U.S. Biomedical Advanced Research and Development Authority announced today.

1 Apr 2011

Biota wins U.S. drug development contract for Laninamivir

Australian biotechnology company Biota Holdings revealed its US subsidiary has won a five year $US231 million ($A224.36 million) contract from the US government to develop a long-acting, single-dose flu drug for sale in the US. Shares in the Melbourne-based drug development company jumped 60 cents, or 57%, to $1.60 at the market open today falling back to $1.43, 1pm (AEST).

31 Mar 2011

Sinovac reports fourth quarter net sales of $9.1 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its fourth quarter and full year financial results periods ended December 31, 2010.

31 Mar 2011

International experts meet to focus on impact of vaccines on global health at a time of public scepticism and complacency

International experts gather in Prague today for a three day meeting focused on the impact of vaccines on public health, at a time of increasing concern that public scepticism and complacency could undermine the positive impact of current and future vaccine campaigns.

31 Mar 2011

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

CEL-SCI Corporation announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in Israel.

31 Mar 2011

WHO Director-General responds to draft report on agency's handling of H1N1 pandemic

WHO Director-General Margaret Chan on Monday responded to the first results of a probe into the agency's response to the H1N1 pandemic, Agence France-Presse reports.

30 Mar 2011

Mexico on swine flu alert again

After four new deaths from swine flu (H1N1), authorities in Mexico's Chihuahua state along the U.S. border announced preventive health measures Sunday to staunch a return of an H1N1 epidemic.

27 Mar 2011

First evidence of H5N1 transmission between domestic farms and wild birds

Wild migratory birds may indeed play a role in the spread of bird flu, also known as highly pathogenic avian influenza H5N1.

25 Mar 2011

New report shows 2% decrease in anxiolytic and hypnotic sales in Norway

After many years of gradual increase followed by a three-year levelling off period, sales of addictive anxiolytic and hypnotic drugs decreased by just under two per cent in 2010.

24 Mar 2011

‘Sleeping sickness’ pandemic offers insight into Parkinson’s

A bizarre disease that caused sufferers to fall into a deep ‘sleep’ while still being aware of their surroundings can offer us insight into the nature of Parkinson’s disease.

21 Mar 2011

Medicago launches clinical development of seasonal flu vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that the first dose of vaccine has been administered thereby initiating the Company's phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States. The primary safety and immunogenicity results for this trial are expected within three months.

21 Mar 2011

Scientists to develop new universal vaccine against various flu viruses

A vaccine that helps against all types of influenza - for several years? If all goes right for Norwegian company Bionor Pharma ASA, such a vaccine could exist within a few years.

17 Mar 2011

EU parliament approves resolution calling for countries to revise pandemic response

On the heels of the release of a draft report by an independent panel of experts examining the WHO's response to H1N1, BMJ News reports on a recently approved resolution and accompanying report released by the European Union parliament that calls on EU countries to revise their flu prevention plans "to make them more effective, coherent, and flexible" and for the WHO to revise its definition of pandemic to take into account not only geographical spread of disease but also severity.

16 Mar 2011

Medicago receives $3.8M as second milestone payment from U.S. DARPA for cGMP vaccine facility

Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the second milestone payment of US$3.8 million from the Defense Advanced Research Projects Agency ("DARPA").

15 Mar 2011

Pandemic News and Research

Further Reading

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Democratic Congresswoman highlights threat climate change poses to public health

Top 10 global pharmaceutical company, Medicago sign deal to develop non-influenza vaccine

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

Biota wins U.S. drug development contract for Laninamivir

Sinovac reports fourth quarter net sales of $9.1 million

International experts meet to focus on impact of vaccines on global health at a time of public scepticism and complacency

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

WHO Director-General responds to draft report on agency's handling of H1N1 pandemic

Mexico on swine flu alert again

First evidence of H5N1 transmission between domestic farms and wild birds

New report shows 2% decrease in anxiolytic and hypnotic sales in Norway

‘Sleeping sickness’ pandemic offers insight into Parkinson’s

Medicago launches clinical development of seasonal flu vaccine

Scientists to develop new universal vaccine against various flu viruses

EU parliament approves resolution calling for countries to revise pandemic response

Medicago receives $3.8M as second milestone payment from U.S. DARPA for cGMP vaccine facility

Best practices - optimize qPCR processes for pathogen detection eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News